Evidence map›Paper›PMID 37803188›Full record

ArticleBiological trace element research2024

Evaluation of the Neuroprotective Effect of Organic Selenium Compounds: An in Vitro Model of Alzheimer's Disease.

Meire Ellen Pereira, Luiza Siqueira Lima, Júlia Vicentin Souza, Nayara de Souza da Costa, Juliana Ferreira da Silva, Izonete Cristina Guiloski, Ana Carolina Irioda, Cláudia Sirlene Oliveira

Abstract read
PubMed Publisher
In one paragraph

Article in Biological trace element research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Meire Ellen PereiraInstituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, PR, Brazil.
Luiza Siqueira LimaInstituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, PR, Brazil.
Júlia Vicentin SouzaInstituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, PR, Brazil.
Nayara de Souza da CostaInstituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, PR, Brazil.
Juliana Ferreira da SilvaInstituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, PR, Brazil.
Izonete Cristina GuiloskiInstituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, PR, Brazil.
Ana Carolina IriodaInstituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, PR, Brazil.
Cláudia Sirlene OliveiraInstituto de Pesquisa Pelé Pequeno Príncipe, Curitiba, PR, Brazil. claudia.bioquimica@yahoo.com.br.
Yahoo (Spain) · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Selenium (Se) is an essential trace element for human health and plays an important role in the development and maintenance of central nervous system functions. Se deficiency has been associated with cognitive decline and increased oxidative stress. The increase in oxidative stress is one of the hypotheses for the emergence and worsening of neurodegenerative diseases, such as Alzheimer's disease (AD). To investigate the neuroprotective effects of organic Se compounds in human neuroblastoma cells (SH-SY5Y) differentiated into cholinergic neurons-like. The SH-SY5Y cells were differentiated into cholinergic neuron-like with retinoic acid (RA) and brain-derived neurotrophic factor (BDNF). AD was mimicked exposing the cells to okadaic acid (OA) and beta-amyloid protein (Aβ). The neuroprotective effect of organic Se compounds, selenomethionine (SeMet) and Ebselen, was evaluated through cell viability tests, acetylcholinesterase and antioxidant enzyme activities, and detection of reactive oxygen species (ROS). None of the SeMet concentrations tested protected against the toxic effect of OA + Aβ. On the other hand, previous exposure to 0.1 and 1 µM Ebselen protected cells from the toxic effect of OA + Aβ. Cell differentiation induced by RA and BDNF exposure was effective, showing characteristics of neuronal cells, and pointing to a promising model of AD. Ebselen showed a protective effect, but more studies are needed to identify the mechanism of action.

Indexed as

Alzheimer DiseaseNeuroprotective AgentsAcetylcholinesteraseAmyloid beta-PeptidesBrain-Derived Neurotrophic FactorCell DifferentiationCell Line, TumorCell SurvivalHumansOrganoselenium CompoundsOxidative StressReactive Oxygen SpeciesSelenium CompoundsSelenomethionineAcetylcholinesteraseAmyloid beta-PeptidesBrain-Derived Neurotrophic FactorNeuroprotective AgentsOrganoselenium CompoundsReactive Oxygen SpeciesSelenium CompoundsSelenomethionineBrazil nutsEbselenNeurodegenerativeSelenium SupplementationSelenomethionine

Identifiers

PMID37803188
OpenAlexW4387394097

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.